F8 IL10

Drug Profile

F8 IL10

Alternative Names: Dekavil; F8-IL10; PF 06687234

Latest Information Update: 06 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Philogen
  • Developer Pfizer; Philogen
  • Class Anti-inflammatories; Antirheumatics; Cytokines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Interleukin-10 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis; Ulcerative colitis
  • Phase I Inflammation

Most Recent Events

  • 15 Jun 2018 Phase-I clinical trials in Ulcerative colitis in USA (IV) (NCT03414788)
  • 13 Jun 2018 Updated efficacy and adverse events data from a phase I trial in Rheumatoid arthritis presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 06 Feb 2018 Pfizer plans a phase I trial for Ulcerative colitis in February 2018 (IV) (NCT03414788)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top